Source: Streetwise Reports Llc

BioWatch News' Alan Leong Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - January 22, 2016) - Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. In some cases he will follow a company's clinical development program and data for years before he pulls the trigger and recommends a name. In this interview with The Life Sciences Report, Leong presents a number of names for investors' consideration. Many won't be mentioned in his usual write-ups: It's an early look at what's on his watch list and in his inbox. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place.

Included in this interview are: ContraVir Pharmaceuticals Inc. (NASDAQ: CTRV) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN).

The Life Sciences Report: Alan, you're a stock analyst, but you also teach entrepreneurship to students at the University of Washington Foster School of Business in Seattle. Tell us about your courses. Do they include labs, field studies, externships, writing business plans?

Alan Leong: It's all of the above. Entrepreneurship is very much hands-on, and there's a lot of interaction among students, professionals and alumni. It's really a wonderful thing. I've seen a number of students, even undergraduates, start amazing, boundary-breaking businesses.

TLSR: Are your students realistic in how much capital they think they will need to start a business? Do they tend to underestimate?

AL: Frankly, they are all over the map. Innovation requires a lot of heterogeneity, and that's the wonderful thing we see in the classroom. Watching students, I have come to the conclusion that…

Continue reading this interview: The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

ContraVir Pharmaceuticals and Rexahn Pharmaceuticals are sponsors of Streetwise Reports. Alan Leong had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Leong and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Contact Information:

Carrie Beal Amaro